Stryker has announced that the FDA has granted PMA for the Surpass Streamline Flow Diverter to treat unruptured large and giant wide neck intracranial aneurysms. The device is the second flow diverting stent to gain FDA approval in the U.S. It is also approved and available in many markets around the world. "Surpass Streamline is the first flow diverter indicated for large and giant posterior communicating artery aneurysms."

Stryker has announced that the U.S. Food and Drug Administration (FDA) has approved the Neuroform Atlas Stent System for marketing under a humanitarian device exemption (HDE). The device is to be utilised in conjunction with neurovascular embolic coils for the treatment of wide neck, intracranial, saccular aneurysms and allows the company to begin U.S. commercialisation efforts immediately.

Stryker has announced that it has received FDA 510(k) clearance for its MultiGen 2 RF Generator. This product provides physicians with the efficiency, control and reliability they need when performing radiofrequency ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain. The MultiGen 2 RF Generator will debut at the Spine Intervention Society's 25th annual meeting, July 19-22, in San Fran...